3.
氨柔比星二线治疗SCLC临床研究[3]
Studies of Amubicin in second line setting
| Author | Type of study | Patient population | No. of patients | Overall response | Median progression free surviva/month | Median survival/month |
| Onoda S, et al[19] | Single Arm | Sensitive | 40 | 52% | 4.2 | 11.6 |
| Refractory | 16 | 50% | 2.6 | 10.3 | ||
| Ettinger D, et al[20] | Single Arm | Refractory | 75 | 17.2% | 3.2 | ---- |
| Jotte RM, et al[22] | Randomized phase Ⅱ | Sensitive | ||||
| Amrubicin | 50 | 34.7% | 4.6 | ---- | ||
| Topotecan | 26 | 3.8% | 3.5 | ---- | ||
| Inoue A, et al[21] | Randomized phase Ⅱ | Sensitive | ||||
| Amrubicin | 17 | 53% | 3.9 | 9.9 | ||
| Topotecan | 19 | 21% | 3.0 | 11.7 | ||
| Refractory | ||||||
| Amrubicin | 12 | 17% | 2.6 | 5.3 | ||
| Topotecan | 11 | 0% | 1.5 | 5.4 |